[1]瞿茹怡,李圣贤,陆咏,等.2q33区基因多态性与Graves病发病风险的研究[J].国际内分泌代谢杂志,2014,(02):77-80.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
　Qu Ruyi*,Li Shengxian,Lu Yong,et al.Association between 2q33 gene polymorphism and Graves' disease[J].International Journal of Endocrinology and Metabolism,2014,(02):77-80.[doi:10.3760/cma.j.issn.1673-4157.2014.02.002]
点击复制

2q33区基因多态性与Graves病发病风险的研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年02期
页码:
77-80
栏目:
论著
出版日期:
2014-04-30

文章信息/Info

Title:
Association between 2q33 gene polymorphism and Graves' disease
作者:
瞿茹怡; 李圣贤; 陆咏; 刘威; 刘炳丽; 宋志毅
200092　上海市第一人民医院分院内科（瞿茹怡,陆咏）；上海交通大学医学院附属仁济医院内分泌科（李圣贤）；200025　上海交通大学医学院附属瑞金医院内分泌科（刘威,刘炳丽,宋志毅） 　　
Author(s):
Qu Ruyi*; Li Shengxian; Lu Yong; Liu Wei; Liu Bingli; Song Zhiyi.
*Department of Internal Medicine,Branch of Shanghai First People's Hospital,Shanghai 200092,China Corresponding author:Lu Yong,Email:hxyly@sohu.com
关键词:
Graves病; 单核苷酸多态性; TagMan-MGB探针; 遗传易感性
Keywords:
Graves' disease; Single nucleotide polymorphism; TagMan-MGB probe; Genetic suscep-tibility
DOI:
10.3760/cma.j.issn.1673-4157.2014.02.002
摘要:
目的　观察2q33区rs1024161（C/T）, rs231726（C/T）和rs10197319（G/A）位点基因多态性与Graves病发病及甲状腺自身抗体间的关系。方法　收集Graves病患者600例及686名正常对照者。采集病史,包括年龄、症状、甲状腺肿、突眼,测定甲状腺激素及甲状腺自身抗体[促甲状腺激素受体抗体（TRAb）、甲状腺过氧化物酶抗体（TPOAb）]。同时留取血标本,抽提DNA,用TagMan-MGB探针法进行基因分型。再分析不同基因型与甲状腺自身抗体（TRAb,TPOAb）的水平,及其与Graves病发病风险的关系。结果　Graves病患者rs1024161和 rs231726 的TT基因型频率（53.67% vs.43.44%,P =0.003 和46.67% vs.38.05%,P =0.002）,rs10197319的GG基因型频率（60.17% vs. 54.08%, P =0.028）均高于对照者。rs1024161（C/T）, rs231726（C/T）和rs10197319（G/A）位点基因多态性与性别、TRAb和TPOAb水平无明显相关性。结论　rs1024161, rs231726和rs10197319位点基因多态性与Graves病的发病相关,2q33为Graves病的易感区段。
Abstract:
Objective　To study the association of the rs1024161（C/T）,rs231726（C/T） and rs10197319（G/A） gene polymorphism with Graves' disease（GD）. Methods　Patients with GD （n =600） and normal control subjects（n =686） were enrolled. History,including age,signs,thyromegaly,and exophthalmos were collected. Meanwhile,the levels of thyrotropin receptor antibody（TRAb） and thyroid peroxidase antibody （TPOAb） were tested. Blood samples were collected to extract DNA,and the genotypes were determined by TagMan-MGB probe. The relationship between different genotypes and the levels of thyroid autoimmune antibodies（TRAb,TPOAb）,and the risk of GD were analyzed. Results　The frequencies of genotype TT of rs1024161,rs231726（53.67% vs. 43.44%,P =0.003；46.67% vs. 38.05%, P =0.002） and genotype GG of rs10197319（60.17% vs. 54.08%,P =0.028） in patients with GD were higher than those in control subjects. There was no association between the rs1024161（C/T）,rs231726（C/T） and rs10197319（G/A） polymorphism with gender,TRAb and TPOAb levels. Conclusion　Rs1024161,rs231726 and rs10197319 polymorphism might have association with GD,and 2q33 region is a susceptible loci of GD.

参考文献/References:

　[1]　Cunninghame Graham DS,Wong AK,McHugh NJ,et al. Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study[J]. Hum Mol Genet,2006,15（21）：3195-3205. 　
[2]　Kim YO,Kim HJ,Kim SK,et al. Association of the CD28/CT-LA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis[J]. Clin Chem Lab Med,2010,48（3）：345-353. 　
[3]　Ei Wafai RJ,Chmaisse HN,Makki RF,et al. Association of HLA class Ⅱ alleles and CTLA-4 polymorphism with type 1 diabetes[J]. Saudi J Kidney Dis Transpl,2011,22（2）：273-281. 　
[4]　Chu X,Pan CM,Zhao SX,et al. A genome-wide association study identifies two new risk loci for Graves' disease[J]. Nat Genet,2011,43（9）：897-901. 　
[5]　Zhao SX,Pan CM,Cao HM,et al. Association of the CTLA4 gene with Graves' disease in the Chinese Han population[J]. PLoS One,2010,5（3）：e9821. 　
[6]　Pastuszak-Lewandoska D,Domańska D,Rudzińska M,et al. CTLA-4 polymorphisms（+49 A/G and -318 C/T） are important genetic determinants of AITD susceptibility and predisposition to high levels of thyroid autoantibodies in Polish children-preliminary study[J]. Acta Biochim Pol,2013,60（4）：641-646. 　
[7]　Pastuszak-Lewandoska D,Sewerynek E,Domańska D,et al. CTLA-4 gene polymorphisms and their influence on predisposi-tion to autoimmune thyroid diseases （Graves' disease and Hashimo-to's thyroiditis）[J]. Arch Med Sci,2012,8（3）：415-421. 　
[8]　Namo Cury A,Longui CA,Kochi C,et al. Graves' disease in Brazilian children and adults：lack of genetic association with CTLA4 +49A＞G polymorphism[J]. Horm Res,2008,70（1）：36-41. 　
[9]　Du L,Yang J,Huang J,et al. The associations between the polymorphisms in the CTLA-4 gene and the risk of Graves' disease in the Chinese population[J].BMC Med Genet,2013,14:46.
[10]　Wang F,Yan T,Chen L,et al. Involvement of inducible costimulator ligand （ICOSL） expression in thyroid tissue in hyper-thyroidism of Graves' disease patients[J]. J Clin Immunol,2012,32（6）：1253-1261.
[11]　Andiappan AK,Nilsson D,Halldén C,et al. Investigating highly replicated asthma genes as candidate genes for allergic rhinitis[J]. BMC Med Genet,2013,14：51.

相似文献/References:

[1]陈晓铭 胡卓清 李潍 刘美莲 吴美芬 方烁 武革.CD40-1C/T多态性（rs1883832）与粤西汉族人Graves病的关系[J].国际内分泌代谢杂志,2015,(01):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
　Chen Xiaoming,Hu Zhuoqing,Li Wei,et al.Relationship between CD40-1C/T polymorphism（rs1883832）and Graves′ disease of Han population in western region of Guangdong province[J].International Journal of Endocrinology and Metabolism,2015,(02):11.[doi:10.3760/cma.j.issn.1673-4157.2015.01.003]
[2]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
　Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(02):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[3]赵永强,田德增,魏晓华,等.不同治疗方法对Graves病患者外周血淋巴细胞亚群的影响[J].国际内分泌代谢杂志,2015,(04):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
　Zhao Yongqiang*,Tian Dezeng,Wei Xiaohua,et al.Effects of different therapeutic methods on peripheral blood lymphocyte subgroups in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2015,(02):234.[doi:10.3760/cma.j.issn.1673-4157.2015.04.005]
[4]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的 相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
　Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(02):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[5]马金刚 魏红丽 尚恒.Graves病患者外周血T细胞亚群与甲状腺 功能及甲状腺自身抗体间的相关性分析[J].国际内分泌代谢杂志,2020,40(01):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
　Ma Jingang,Wei Hongli,Shang Heng.Correlation between peripheral blood T cell subsets and thyroid function and thyroid autoantibodies in patients with Graves' disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):21.[doi:10.3760/cma.j.issn.1673-4157.2020.01.005]
[6]陈莹 倪文婧 陈国芳 徐书杭.基于复发危险因素探讨Graves病治疗的新策略[J].国际内分泌代谢杂志,2022,42(04):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
　Chen Ying,Ni Wenjing,Chen Guofang,et al.New strategies for the treatment of Graves' disease based on risk factors of relapse[J].International Journal of Endocrinology and Metabolism,2022,42(02):260.[doi:10.3760/cma.j.cn121383-20210412-04031]
[7]陈莹 徐书杭.2022年欧洲甲状腺学会《儿童Graves病管理指南》解读[J].国际内分泌代谢杂志,2023,43(05):449.[doi:10.3760/cma.j.cn121383-20220629-06064]
　Chen Ying,Xu Shuhang.Interpretation of 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease[J].International Journal of Endocrinology and Metabolism,2023,43(02):449.[doi:10.3760/cma.j.cn121383-20220629-06064]

备注/Memo

备注/Memo:
通信作者：陆咏,Email:hxyly@sohu.com
更新日期/Last Update: 2014-03-20